Get started
Author

Anna Guidetti

Observed names: A Guidetti, A. Guidetti, Anna GUIDETTI, Guidetti Anna, Guidetti, Anna
Observed institutions: University of Insubria, University of Parma, Karolinska University Hospital, University of Milan, National and Kapodistrian University of Athens, Instituto de Salud Carlos III, Biomedical Primate Research Centre, Hospital General Universitario Gregorio Marañón, Istituti Clinici Scientifici Maugeri, Hospital Universitario Puerta de Hierro Majadahonda, University Medical Center Hamburg-Eppendorf, Hospital Universitario de Burgos, IRCCS Ospedale San Raffaele, King's College Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Centre Hospitalier de Versailles, IRCCS Humanitas Research Hospital, Aziende Socio Sanitarie Territoriale dei Sette Laghi, University of Turin
ORCID: 0000-0002-4195-6397
Observed ORCID: 0000-0002-4195-6397
OpenAlex ID: A5064544139
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
2021 · Livio Pagano, Jon Salmanton-García, et al. · Journal of Hematology & Oncology · 316
PDF
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
2022 · Margherita Maffioli, Barbara Mora, et al. · Blood Advances · 128
PDF
Genetic and phenotypic attributes of splenic marginal zone lymphoma
2021 · Ferdinando Bonfiglio, Alessio Bruscaggin, et al. · Blood · 97
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
2021 · Vincenzo Marasco, Cristiana Carniti, et al. · British Journal of Haematology · 95
PDF
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
2022 · Livio Pagano, Jon Salmanton-García, et al. · Blood · 91
PDF
Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination
2004 · Massimo Di Nicola, Carmelo Carlo-Stella, et al. · Clinical Cancer Research · 84
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
2021 · Reid W. Merryman, Luca Castagna, et al. · Leukemia · 82
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
2021 · Alessandro Busca, Jon Salmanton-García, et al. · Blood Advances · 78
Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
2022 · Ola Blennow, Jon Salmanton‐García, et al. · American Journal of Hematology · 74
PDF
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
2022 · Chiara Monfrini, Federico Stella, et al. · Clinical Cancer Research · 72
PDF
High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation
2008 · Liliana Devizzi, Anna Guidetti, et al. · Journal of Clinical Oncology · 71
PDF
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
2018 · Marek Trnĕný, Gregor Verhoef, et al. · Haematologica · 63
PDF
Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma
2006 · Marco Ladetto, Michele Magni, et al. · Transplantation and Cellular Therapy · 60
PDF
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
2021 · Carlo Visco, Luigi Marcheselli, et al. · Blood Advances · 55
PDF
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers
2004 · Carmelo Carlo-Stella, Massimo Di Nicola, et al. · Blood · 53
PDF
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
2019 · A. Dodero, A. Guidetti, et al. · Leukemia · 48
PDF
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone
2004 · Carmelo Carlo-Stella, Massimo Di Nicola, et al. · Experimental Hematology · 48
PDF
Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells
2013 · Carmelo Carlo-Stella, Silvia L. Locatelli, et al. · PLoS ONE · 45
PDF
Phase II study of sorafenib in patients with relapsed or refractory lymphoma
2012 · Anna Guidetti, Carmelo Carlo‐Stella, et al. · British Journal of Haematology · 42
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
2021 · Anna Dodero, Anna Guidetti, et al. · Haematologica · 40
PDF
High response rate and manageable toxicity with an intensive, short‐term chemotherapy programme for Burkitt's lymphoma in adults
2004 · Massimo Di Nicola, Carmelo Carlo‐Stella, et al. · British Journal of Haematology · 38
PDF
Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases
2014 · Anna Guidetti, Carmelo Carlo-Stella, et al. · Clinical Cancer Research · 36
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
2024 · Jon Salmanton-García, Francesco Marchesi, et al. · EClinicalMedicine · 35
PDF
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
2024 · Annalisa Chiappella, Beatrice Casadei, et al. · Leukemia · 35
PDF
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
2023 · Jon Salmanton-García, Francesco Marchesi, et al. · EClinicalMedicine · 34
Works count: 186
Citation count: 2,676
H-index: 28
I10-index: 63
Year
Topic
Type